Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Asset Writedowns and Impairment (2019 - 2025)

Akebia Therapeutics (AKBA) has disclosed Asset Writedowns and Impairment for 7 consecutive years, with $2.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Asset Writedowns and Impairment fell 36.0% to $2.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.5 million, a 40.47% decrease, with the full-year FY2025 number at $2.5 million, down 40.47% from a year prior.
  • Asset Writedowns and Impairment was $2.5 million for Q4 2025 at Akebia Therapeutics, up from -$163000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $5.3 million in Q1 2022 to a low of -$9.6 million in Q4 2022.
  • A 5-year average of $397944.4 and a median of $495000.0 in 2021 define the central range for Asset Writedowns and Impairment.
  • Biggest YoY gain for Asset Writedowns and Impairment was 3569.06% in 2021; the steepest drop was 546.64% in 2021.
  • Akebia Therapeutics' Asset Writedowns and Impairment stood at -$7.1 million in 2021, then tumbled by 34.63% to -$9.6 million in 2022, then skyrocketed by 86.17% to -$1.3 million in 2023, then surged by 394.95% to $3.9 million in 2024, then crashed by 36.0% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Asset Writedowns and Impairment are $2.5 million (Q4 2025), -$163000.0 (Q2 2025), and $163000.0 (Q1 2025).